Cantor Fitzgerald reaffirmed its Overweight rating on Neurocrine Biosciences stock (NASDAQ:NBIX) with a consistent price target of $170.00. Currently trading at $150.51, the stock has shown strong ...

As previously reported last night, Cantor Fitzgerald analyst Colin Canfield initiated coverage of five Government Technology & Space, or ...

Will the Senate GOP confirm controversial picks like Tulsi Gabbard and RFK Jr.? Here’s the hearings schedule and list of ...

Cantor Fitzgerald adjusted its price target for Fortinet shares (NASDAQ:FTNT) to $115.00, an increase from the previous target of $110.00. The firm maintained a Neutral stance on the cybersecurity ...

In a report released today, Deepak Mathivanan from Cantor Fitzgerald maintained a Hold rating on Expedia (EXPE – Research Report), with a price ...

It’s not that the Trump administration is anti-Goldman Sachs, sources say, but rather there just isn’t as much talent to take ...

Analysts at Cantor Fitzgerald lowered their FY2025 EPS estimates for shares of PTC Therapeutics in a report released on ...

Cantor Fitzgerald boosted their FY2025 earnings per share estimates for shares of Palantir Technologies in a report released on Tuesday, February 4th. Cantor Fitzgerald analyst T. Blakey now ...

LKQ Corporation (LKQ) filed suit against Robert Rutledge, its former plant manager, in the U.S. District Court for the Northern District ...

Lutnick is CEO of Cantor Fitzgerald, previous owner of Cantor Gaming. The company reportedly violated state and federal ...